|
| |
ISTA PharmaceuticalsISTA Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of unique and uniquely improved ophthalmic products for serious conditions of the eye.
ISTA has three approved products, Xibrom™ (for the treatment of ocular inflammation following cataract surgery), Istalol® (for the treatment of glaucoma) and Vitrase® (for use as a "spreading agent"). We launched Istalol® during Q3 2004, Vitrase® during Q1 2005 and Xibrom™ during Q2 2005. We have received an approvable letter for Vitrase® (for the treatment of vitreous hemorrhage). We have other prescription products under development, including a tobramycin prednisolone acetate for the treatment of inflammation where a bacterial infection might be present, ecabet sodium, for the treatment of dry eye, and Caprogel® for the treatment of hyphema.
In order to further build our pipeline as a specialty pharmaceutical company, we expect to acquire complementary products in ophthalmology, either already marketed or in late-stage development. ISTA has been well financed, and our management team has extensive experience in the development and commercialization of ophthalmic pharmaceuticals.
| Contact Details: |
| 15295 Alton Parkway |
| Irvine |
| California |
| 92618 |
| United States of America |
| Tel: | (949) 788-6000 |
| Fax: | (949) 788-6010 |
| Email: | |
| WWW: | www.istavision.com/
|
|
Loading...
|
Recent Publications by ISTA Pharmaceuticals: |  |
24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits.
PURPOSE: The aim of this study was to determine the distribution and... | 6th January, 2009
| ISTA Pharmaceuticals(R), Inc., Irvine, CA 92618, USA.
| J Ocul Pharmacol Ther. 2008 Aug;24(4):392-8.
DOI Direct Link |
Evaluation of aqueous humor concentrations of Istalol and Betimol following a single ocular instillation in rabbit eyes.
PURPOSE: The aim of this study was to evaluate the pharmacokinetic... | 17th December, 2008
| ISTA Pharmaceuticals,
| J Ocul Pharmacol Ther. 2008 Oct;24(5):507-12.
DOI Direct Link |
Pupil dilatation in response to vagal afferent electrical stimulation is mediated by inhibition of parasympathetic outflow in the rat.
Pupil dilatation (PD) was produced by vaginocervical mechanical... | 16th January, 2008
| Clinical Research, ISTA Pharmaceuticals, Inc. 15295 Alton Parkway, Irvine,
| Brain Res. 2007 Oct 26;1177:29-36. Epub 2007 Aug 11.
DOI Direct Link |
Licensing Compounds: lessons from ISTA Pharmaceuticals.
Pupil dilatation (PD) was produced by vaginocervical mechanical... | 2nd March, 2006
| ISTA Pharmaceuticals, Irvine, CA, USA.
| Retina. 2005 Dec;25(8 Suppl):S98.
|
Crucial factors in commercial success for ophthalmic drugs.
Pupil dilatation (PD) was produced by vaginocervical mechanical... | 2nd March, 2006
| ISTA Pharmaceuticals, Inc., Irvine, CA, USA.
| Retina. 2005 Dec;25(8 Suppl):S109.
|
→View more ISTA Pharmaceuticals research publications. |
Press Releases on ISTA Pharmaceuticals:
|
 |
| ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) |
9th November, 2009 |
ISTA Pharmaceuticals, Inc. |
MIAMI, Nov. 9 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5
|
| ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results |
3rd November, 2009 |
ISTA Pharmaceuticals, Inc. |
Net Revenue
(in millions, except percentage data)
Three Months Three Months Nine Months Nine Months
|
| ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the American College of Clinical Pharmacy (ACCP) 2009 Annual Meeting |
21st October, 2009 |
ISTA Pharmaceuticals, Inc. |
ANAHEIM, Calif., Oct. 21 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate
|
| ISTA Pharmaceuticals to Present at 2009 BIOCOM Investor Conference |
20th October, 2009 |
ISTA Pharmaceuticals, Inc. |
IRVINE, Calif., Oct. 20 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will present at the 2009 BIOCOM Investor Conference at 11:30 a.m. Pacific Time on
|
| ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results |
2nd October, 2009 |
ISTA Pharmaceuticals, Inc. |
IRVINE, Calif., Oct. 2 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will release third quarter 2009 financial results after market close on November 3, 2009.
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 550 times since April 2007, the link to the organisation's website has been followed 74 times Recent Search Terms used to find this page: ista pharmaceuticals email | ISTALOL patent | ista pharmaceuticals | ISTA specialty pharm | ista pharmaceuticals | ISTA irvine ca | ista pharm inc calif | bepotastine besilate product | ista vision | ista pharmaceuticals | . Search for more companies in Irvine Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for ISTA Pharmaceuticals |
